# Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects

> **NCT02054754** · PHASE1 · COMPLETED · sponsor: **e-Therapeutics PLC** · enrollment: 40 (actual)

## Conditions studied

- Safety
- Tolerability
- Pharmacokinetics
- Cancer

## Interventions

- **DRUG:** Dexanabinol Dose Level 1
- **DRUG:** Dexanabinol Dose Level 2
- **DRUG:** Dexanabinol Dose Level 3
- **DRUG:** Dexanabinol Dose Level 4
- **DRUG:** Dexanabinol Dose Level 5
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02054754
- **Lead sponsor:** e-Therapeutics PLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2014-09
- **Final completion:** 2014-09
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02054754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02054754, "Assessment of Single Doses of Oral Dexanabinol in Healthy Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02054754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*